DTTDoan Thanh TungBAVideoHealth Innovations to Reduce the Impact of Stigma in HIV/STI Care 2025TAP4S Initiative: From Click to Clinic – A Flexible HIV/STI Care Continuum Model by Lighthouse Vietnam - Doan Thanh TungView Video
Video23rd European Meeting on HIV & Hepatitis 2025Quick Recap: 23rd European Meeting on HIV & Hepatitis 2025View Video
Video1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Injectable Formulation of Ivermectin as a New Vector Control Tool to Reduce Malaria Transmission - Quiterie Savary de BeauregardView Video
VideoViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #4 Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results - Yasmin IbrahimView Video
VideoHIVTuberculosisViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna GaayebView Video
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Video
VideoTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Video
VideoTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Video
VideoNTDTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina KovarovaView Video
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #2 Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) - Meredith ClementView Video
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #5 Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV Viral Suppression, Perinatal and Neonatal Outcomes - William ShortView Video
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #4 Facilitators and Barriers to Long-Acting Injectable Antiretroviral Therapy Uptake among Youth Living with HIV in Cape Town, South Africa: A COM-B Analysis - Sheree SchwartzView Video
